Novartis Ag (NVS) Other Non-Current Assets (2009 - 2026)
Novartis Ag (NVS) posted Other Non-Current Assets of $5.9 billion for Q2 2026, up 2863.0% sequentially from $200.0 million in Q1 2026, and up 32.45% YoY from $4.5 billion in Q2 2025.
Novartis Ag (NVS) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Novartis Ag has reported Other Non-Current Assets for 18 years, with the latest figure at $5.9 billion in Q2 2026.
- Quarterly Other Non-Current Assets rose 32.45% year-over-year to $5.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.9 billion (up 32.45% YoY) and the FY2025 annual result came in at $5.3 billion, up 50.5% from the prior year.
- Other Non-Current Assets rose to $5.9 billion in Q2 2026 per NVS's latest filing, from $200.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $5.9 billion in Q2 2026 and troughed at $200.0 million in Q1 2026.
- A 5-year average of $2.8 billion and a median of $2.6 billion in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets sank 68.91% in 2023, then soared 192.33% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.1 billion in 2022, then advanced by 8.02% to $1.2 billion in 2023, then jumped by 192.33% to $3.5 billion in 2024, then soared by 50.5% to $5.3 billion in 2025, then grew by 12.34% to $5.9 billion in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.9 billion, $200.0 million, and $5.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Bn |
| Mar 31, 2026 | 200.00 Mn |
| Dec 31, 2025 | 5.28 Bn |
| Jun 30, 2025 | 4.47 Bn |
| Dec 31, 2024 | 3.51 Bn |
| Jun 30, 2024 | 1.66 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Jun 30, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.11 Bn |
| Jun 30, 2022 | 3.89 Bn |
| Dec 31, 2021 | 2.21 Bn |
| Jun 30, 2021 | 2.21 Bn |
| Dec 31, 2020 | 892.00 Mn |
| Sep 30, 2020 | 850.00 Mn |
| Jun 30, 2020 | 866.00 Mn |
| Mar 31, 2020 | 988.00 Mn |
| Dec 31, 2019 | 738.00 Mn |
| Sep 30, 2019 | 689.00 Mn |
| Jun 30, 2019 | 703.00 Mn |
| Mar 31, 2019 | 626.00 Mn |